Q3 highlights: growth in all product lines, +15% in constant currencies
Continued strong sales in USA driven by
OEM
Instrument sales increasing globally
Consumables up +12% vs 2020, but still impacted by COVID-19 restrictions, in particular in Southeast Asia
Disturbances in the supply chain impact profitability
Good progress with our strategic priorities
Entering Q4 with large order book
COVID
recovery
Positive R12 trends for both instruments and consumables continues
Boule Diagnostics
November 10, 2021
Consumable sales recovering
Growth in all product lines
Net sales in constant currencies up +15% YoY, +1% QoQ
Regional mix as well as supply chain disturbances pressure gross margin
Investments in new platform 11 MSEK
Boule Diagnostics
November 10, 2021
Financials Q3
Net sales, MSEK
Gross margin
111.8
44.7%
YoY Growth
EBIT-margin
13.2%
11.7%
Op. cash-flow, MSEK
10.6
Sales bridge: positive trends
● Recovery driven by ease of pandemic
● Growth in US +20% in fixed currencies, driven
restrictions across the world
mainly by OEM business
OEM business continue to show strong ● Asia growth driven by instrument and consumable
performance
sales to India. Still restrictions in many other
countries
● Last year Q3: larger tender sales in West Europe
Boule Diagnostics
November 10, 2021
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Boule Diagnostics AB published this content on 10 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 November 2021 07:54:04 UTC.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
